ANI Pharma (ANIP) Tops Q3 EPS by 43c

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $1.27, $0.43 better than the analyst estimate of $0.84. Revenue for the quarter came in at $131.83 million versus the consensus estimate of $111.92 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance